Literature DB >> 3007497

[mono[125I]iodo-Tyr10,MetO17]-vasoactive intestinal polypeptide. Preparation, characterization, and use for radioimmunoassay and receptor binding.

J L Martin, K Rose, G J Hughes, P J Magistretti.   

Abstract

Vasoactive intestinal polypeptide (VIP) was labeled with sodium [125I]iodide using the chloramine-T method and subsequently purified by reverse-phase high performance liquid chromatography. Three main 125I-labeled peaks designated A, B, and C resulted from the radioiodination and purification procedures. They were characterized by electrophoresis of tryptic fragments; Edman degradation (for Peaks A and C); enzymatic digestion to amino acids by leucine aminopeptidase, carboxypeptidase Y and Pronase; and treatment with cyanogen bromide. Peak A corresponds to VIP monoiodinated on Tyr10 and with the Met17 residue oxidized to methionine sulfoxide. This [mono[125I]iodo-Tyr10,MetO17]VIP displays the following characteristics. 1) It constitutes quantitatively the major product of the iodination procedure (62.5%); 2) it is well resolved from other labeled and unlabeled products; 3) it is stable (2 months at -20 degrees C); 4) it possesses a high specific activity (2050 Ci/mmol); 5) it maintains the biological activity of native VIP; and 6) it binds to antibody and membrane recognition sites in a specific, saturable, and reversible manner. Reduction of [mono[125I]iodo-Tyr10, Met-O17]VIP to [mono[125I]iodo-Tyr10]VIP does not improve the performance of the tracer in a radioimmunoassay. The method described in this article is simple and rapid and yields a molecular form of 125I-labeled VIP that has been fully characterized and is suitable for use in biological studies.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3007497

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Identification of pituitary adenylate cyclase-activating polypeptide1-38-binding factor in human plasma, as ceruloplasmin.

Authors:  J W Tams; A H Johnsen; J Fahrenkrug
Journal:  Biochem J       Date:  1999-07-15       Impact factor: 3.857

2.  Photoaffinity labelling of the vasoactive-intestinal-peptide-binding site on intact human colonic adenocarcinoma cell line HT29-D4. Synthesis and use of photosensitive vasoactive-intestinal-peptide derivatives.

Authors:  J M Martin; H Darbon; J Luis; A el Battari; J Marvaldi; J Pichon
Journal:  Biochem J       Date:  1988-03-15       Impact factor: 3.857

3.  Role of second extracellular loop in the function of human vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide receptor 1 (hVPAC1R).

Authors:  S M Knudsen; J W Tams; J Fahrenkrug
Journal:  J Mol Neurosci       Date:  2000-06       Impact factor: 3.444

4.  Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro.

Authors:  Christine Dufes; Céline Alleaume; Alicia Montoni; Jean-Christophe Olivier; Jean-Marc Muller
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

5.  The effects of a high sodium diet on the metabolism and secretion of vasoactive intestinal peptide in the rabbit.

Authors:  R E Davis; S Shelley; G J MacDonald; K A Duggan
Journal:  J Physiol       Date:  1992       Impact factor: 5.182

6.  Activation of VPAC1 receptors by VIP and PACAP-27 in human bronchial epithelial cells induces CFTR-dependent chloride secretion.

Authors:  Renaud Dérand; Alicia Montoni; Laurence Bulteau-Pignoux; Thierry Janet; Bertrand Moreau; Jean-Marc Muller; Frédéric Becq
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

7.  Effects of chronic airway inflammation on the activity and enzymatic inactivation of neuropeptides in guinea pig lungs.

Authors:  C M Lilly; L Kobzik; A E Hall; J M Drazen
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

8.  Peptidase modulation of vasoactive intestinal peptide pulmonary relaxation in tracheal superfused guinea pig lungs.

Authors:  C M Lilly; M A Martins; J M Drazen
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

Review 9.  Radiolabeled Dendrimers for Nuclear Medicine Applications.

Authors:  Lingzhou Zhao; Meilin Zhu; Yujie Li; Yan Xing; Jinhua Zhao
Journal:  Molecules       Date:  2017-08-25       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.